Long-acting injectable antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities August 26, 2019 August 26, 2019
Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development July 9, 2019 July 9, 2019
Shareholders audioconference and publication of the results for the 2018-2019 financial year, on June 4, 2019 May 22, 2019 May 22, 2019
MedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management March 11, 2019 March 11, 2019
MedinCell receives funding for the second formulation phase of its 6-month injectable contraceptive January 24, 2019 January 24, 2019
Publication of the activity report and financial information for the first half-year (April – Sept. 2018) December 3, 2018 December 3, 2018
Publication of the activity report and financial information for the first half-year on December 3, 2018 November 27, 2018 November 27, 2018
Partial exercise of the over-allotment option – Final amount of the share issue increased to €31.4m November 5, 2018 November 5, 2018
